Novo Nordisk has appointed Maziar Mike Doustdar as CEO, replacing Lars Fruergaard, to address recent market challenges.

Danish leader will face a challenging landscape among competitors ...

Novo Nordisk A/S (NYSE:NVO) is one of the top 10 medical AI companies to buy according to analysts. On July 29, Novo Nordisk ...

Delhi: Global healthcare major Novo Nordisk has announced the appointment of Maziar Mike Doustdar as its new President and ...

Novo Nordisk, a Danish multinational pharmaceutical company headquartered in Bagsværd with production facilities in nine ...

Novo Nordisk's new CEO, Maziar Mike Doustdar, is tasked with revitalizing the company's flagging sales and addressing ...

President Donald Trump says pharma tariffs could go as high as 250%. UBS downgrades Novo Nordisk stock to neutral and lowers ...

Novo Nordisk (NYSE: NVO) stock is testing the patience of buy-and-hold investors. Over the last five years, NVO stock is up more than 200%. However, in the last year, it’s down over 61% and more than ...

Novo Nordisk is scheduled to report results for the second quarter on Wednesday. Here is what you need to know: PROFIT FORECAST: The company pre-released preliminary second-quarter numbers last week, ...

CEO-to-be Maziar Mike Doustdar will need to stem the company’s tumbling share price as market pressures intensify.

Novo Nordisk A/S’s best-sellers Ozempic and Wegovy transformed the firm into a global pharmaceutical giant. But four years ...

As a Barclays analyst put it, it’s been a “slow-moving car crash”. Early supply shortages pushed patients to competitors, ...